Antifungal Activity of the Biphosphinic Cyclopalladate C7a Against Yeast Forms and

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2017 May 19

PMID 28515716

Citations 9

Authors

Julian E Munoz

Diego C P Rossi

Kelly Ishida

Cristina C Spadari

Marcia S C Melhem

Daniel M Garcia

Antonio C F Caires

Carlos P Taborda

Elaine G Rodrigues

Affiliations

Soon will be listed here.

Abstract

Vulvovaginal and invasive candidiasis are frequent conditions in immunosuppressed individuals caused by and non- spp. Fluconazole and Amphotericin B are the main drugs used to fight the infection. However, resistance to fluconazole and other azole antifungal drugs is an important clinical problem that encourages the search for new therapeutic alternatives. In this work, we evaluate the antifungal activity of the biphosphinic cyclopalladate C7a in the and model. Our results showed fungicidal activity, with low values of minimal inhibitory concentrations and minimum fungicidal concentrations, even for fluconazole and/or miconazole resistant isolates. Fluorescence microscopy and transmission electron microscopy revealed that the compound was able to inhibit the formation of hyphae/pseudohyphae and, moreover, promoted morphological alterations in cellular organelles and structures, such as disruption of cell wall, apparent mitochondrial swelling, chromatin marginalization into the nuclei and increased numbers of electron-lucent vacuoles. C7a significantly decreased the biofilm formation and reduced the viability of yeast cells in mature biofilms when tested against a virulent strain. assays demonstrated a significant decrease of fungal burden in local (vaginal canal) and disseminated (kidneys) infection. In addition, we observed a significant increase in the survival of the systemically infected animals treated with C7a. Our results suggest C7a as a novel therapeutic agent for vaginal and disseminated candidiasis, and an alternative for conventional drug-resistant .

Citing Articles

A simplified version of rapid susceptibility testing of bacteria and yeasts using optical nanomotion detection.

Villalba M, Gligorovski V, Rahi S, Willaert R, Kasas S Front Microbiol. 2024; 15:1328923.

PMID: 38516011 PMC: 10956355. DOI: 10.3389/fmicb.2024.1328923.

The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.

Gomaa S, Abbas H, Mohamed F, Ali M, Ibrahim T, Halim A BMC Microbiol. 2024; 24(1):54.

PMID: 38341568 PMC: 10858509. DOI: 10.1186/s12866-024-03181-z.

In Vitro Antifungal Activity of Three Synthetic Peptides against and Other Species of Medical Importance.

Torres R, Barreto-Santamaria A, Arevalo-Pinzon G, Firacative C, Gomez B, Escandon P Antibiotics (Basel). 2023; 12(8).

PMID: 37627654 PMC: 10451292. DOI: 10.3390/antibiotics12081234.

Novel Preclinical Study of Galloylquinic Acid Compounds from with Potent Antifungal Activity against Vaginal Candidiasis Induced in a Murine Model via Multitarget Modes of Action.

Al-Madboly L, El-Salam M, Bastos J, El-Shorbagy S, El-Morsi R Microbiol Spectr. 2022; 10(5):e0272421.

PMID: 35972130 PMC: 9603814. DOI: 10.1128/spectrum.02724-21.

Therapeutic Potential of Perillaldehyde in Ameliorating Vulvovaginal Candidiasis by Reducing Vaginal Oxidative Stress and Apoptosis.

Chen L, Wang F, Qu S, He X, Zhu Y, Zhou Y Antioxidants (Basel). 2022; 11(2).

PMID: 35204061 PMC: 8868166. DOI: 10.3390/antiox11020178.

References

Rodrigues E, Silva L, Fausto D, Hayashi M, Dreher S, Santos E . Cyclopalladated compounds as chemotherapeutic agents: antitumor activity against a murine melanoma cell line. Int J Cancer. 2003; 107(3):498-504. DOI: 10.1002/ijc.11434. View

Gil C, Pomes R, Nombela C . Isolation and characterization of Candida albicans morphological mutants derepressed for the formation of filamentous hypha-type structures. J Bacteriol. 1990; 172(5):2384-91. PMC: 208873. DOI: 10.1128/jb.172.5.2384-2391.1990. View

Hassan I, Powell G, Sidhu M, Hart W, Denning D . Excess mortality, length of stay and cost attributable to candidaemia. J Infect. 2009; 59(5):360-5. DOI: 10.1016/j.jinf.2009.08.020. View

Mukherjee P, Chandra J, Kuhn D, Ghannoum M . Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun. 2003; 71(8):4333-40. PMC: 165995. DOI: 10.1128/IAI.71.8.4333-4340.2003. View

Andes D, Diekema D, Pfaller M, Prince R, Marchillo K, Ashbeck J . In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2007; 52(2):539-50. PMC: 2224754. DOI: 10.1128/AAC.01061-07. View

Matsuo A, Silva L, Torrecilhas A, Pascoalino B, Ramos T, Rodrigues E . In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease. Antimicrob Agents Chemother. 2010; 54(8):3318-25. PMC: 2916297. DOI: 10.1128/AAC.00323-10. View

Arruda D, Matsuo A, Silva L, Real F, Leitao Jr N, Pires J . Cyclopalladated Compound 7a Induces Apoptosis- and Autophagy-Like Mechanisms in Paracoccidioides and Is a Candidate for Paracoccidioidomycosis Treatment. Antimicrob Agents Chemother. 2015; 59(12):7214-23. PMC: 4649154. DOI: 10.1128/AAC.00512-15. View

Mayer F, Wilson D, Hube B . Candida albicans pathogenicity mechanisms. Virulence. 2013; 4(2):119-28. PMC: 3654610. DOI: 10.4161/viru.22913. View

Campoy S, Adrio J . Antifungals. Biochem Pharmacol. 2016; 133:86-96. DOI: 10.1016/j.bcp.2016.11.019. View

10.

Harper B, Krause-Heuer A, Grant M, Manohar M, Garbutcheon-Singh K, Aldrich-Wright J . Advances in platinum chemotherapeutics. Chemistry. 2010; 16(24):7064-77. DOI: 10.1002/chem.201000148. View

11.

Sobel J . Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2015; 214(1):15-21. DOI: 10.1016/j.ajog.2015.06.067. View

12.

Pappas P, Kauffman C, Andes D, Clancy C, Marr K, Ostrosky-Zeichner L . Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015; 62(4):e1-50. PMC: 4725385. DOI: 10.1093/cid/civ933. View

13.

Caires A . Recent advances involving palladium (II) complexes for the cancer therapy. Anticancer Agents Med Chem. 2007; 7(5):484-91. DOI: 10.2174/187152007781668661. View

14.

Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M . Candidemia and invasive candidiasis in adults: A narrative review. Eur J Intern Med. 2016; 34:21-28. DOI: 10.1016/j.ejim.2016.06.029. View

15.

Serrano F, Matsuo A, Monteforte P, Bechara A, Smaili S, Santana D . A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells. BMC Cancer. 2011; 11:296. PMC: 3156809. DOI: 10.1186/1471-2407-11-296. View

16.

Guimaraes-Correa A, Crawford L, Figueiredo C, Gimenes K, Pinto L, Grassi M . C7a, a biphosphinic cyclopalladated compound, efficiently controls the development of a patient-derived xenograft model of adult T cell leukemia/lymphoma. Viruses. 2011; 3(7):1041-1058. PMC: 3185797. DOI: 10.3390/v3071041. View

17.

Hamad M, Abu-Elteen K, Ghaleb M . Estrogen-dependent induction of persistent vaginal candidosis in naïve mice. Mycoses. 2004; 47(7):304-9. DOI: 10.1111/j.1439-0507.2004.00994.x. View

18.

Anderson M, Klink K, Cohrssen A . Evaluation of vaginal complaints. JAMA. 2004; 291(11):1368-79. DOI: 10.1001/jama.291.11.1368. View

19.

Rossi D, Munoz J, Carvalho D, Belmonte R, Faintuch B, Borelli P . Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis. BMC Microbiol. 2012; 12:28. PMC: 3361493. DOI: 10.1186/1471-2180-12-28. View

20.

Cabib E . The septation apparatus, a chitin-requiring machine in budding yeast. Arch Biochem Biophys. 2004; 426(2):201-7. DOI: 10.1016/j.abb.2004.02.030. View